Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
University of Chicago
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
68High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07355205CT.gov First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07563738CT.gov A 2-part Phase 1/2 Open-label Trial on ODM-212 | — | Recruiting | — | — | — |
NCT07154290CT.gov A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT07394062CT.gov Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01) | — | Recruiting | — | — | — |
NCT07526961CT.gov Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland | — | Completed | — | — | — |
NCT06946797CT.gov A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) | — | Active Not Recruiting | — | — | — |
NCT06364917CT.gov DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC | — | Recruiting | — | — | — |
NCT06926790CT.gov Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3) | — | Recruiting | — | — | — |
NCT07215962CT.gov Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1% | — | Active Not Recruiting | — | — | — |
NCT07024862CT.gov Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy | — | Active Not Recruiting | — | — | — |
Show 81 more trialsShow fewer
NCT06362369CT.gov A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | — | Recruiting | — | — | — |
NCT06492421CT.gov Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer. | — | Recruiting | — | — | — |
NCT06047379CT.gov Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | — | Recruiting | — | — | — |
NCT06487156CT.gov A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05715229CT.gov Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy | — | Recruiting | — | — | — |
NCT05933265CT.gov Study of LP-184 in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05501665CT.gov Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | — | Recruiting | — | — | — |
NCT05597800CT.gov Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome | — | Not Yet Recruiting | — | — | — |
NCT05401786CT.gov Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC | — | Active Not Recruiting | — | — | — |
NCT05598853CT.gov Intrathecal Double Checkpoint Inhibition | — | Active Not Recruiting | — | — | — |
NCT04929041CT.gov Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative | — | Suspended | — | — | — |
NCT05005273CT.gov A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT05317858CT.gov Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets | — | Recruiting | — | — | — |
NCT04966676CT.gov Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer | — | Terminated | — | — | — |
NCT05176483CT.gov Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors | — | Recruiting | — | — | — |
NCT05012254CT.gov Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases | — | Active Not Recruiting | — | — | — |
NCT04933903CT.gov BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab | — | Recruiting | — | — | — |
NCT04940299CT.gov Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma | — | Active Not Recruiting | — | — | — |
NCT04151563CT.gov A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy | — | Withdrawn | — | — | — |
NCT04665206CT.gov Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT04591431CT.gov The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | — | Unknown | — | — | — |
NCT04571632CT.gov Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors | — | Unknown | — | — | — |
NCT04141644CT.gov Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC | — | Active Not Recruiting | — | — | — |
NCT04074967CT.gov Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | — | Active Not Recruiting | — | — | — |
NCT04250246CT.gov A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 | — | Unknown | — | — | — |
NCT04026412CT.gov A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery | — | Completed | — | — | — |
NCT04013542CT.gov Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04043195CT.gov Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC | — | Active Not Recruiting | — | — | — |
NCT03953235CT.gov A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | — | Completed | — | — | — |
NCT03645928CT.gov Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | — | Terminated | — | — | — |
NCT03752398CT.gov A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) | — | Completed | — | — | — |
NCT03907852CT.gov Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | — | Active Not Recruiting | — | — | — |
NCT03647163CT.gov Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03639714CT.gov A Study of a Personalized Neoantigen Cancer Vaccine | — | Completed | — | — | — |
NCT03663166CT.gov Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT03573947CT.gov Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC | — | Completed | — | — | — |
NCT03515629CT.gov REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer | — | Terminated | — | — | — |
NCT03509584CT.gov Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients | — | Terminated | — | — | — |
NCT03430063CT.gov A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer | — | Terminated | — | — | — |
NCT03520686CT.gov Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03527251CT.gov Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC | — | Unknown | — | — | — |
NCT03468985CT.gov Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT03469960CT.gov Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr | — | Completed | — | — | — |
NCT03425331CT.gov Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC | — | Terminated | — | — | — |
NCT03048136CT.gov A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT03409614CT.gov Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer | — | Completed | — | — | — |
NCT03351361CT.gov Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients | — | Completed | — | — | — |
NCT03377023CT.gov Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT03391869CT.gov Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT03302234CT.gov Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598) | — | Completed | — | — | — |
NCT03168464CT.gov Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) | — | Terminated | — | — | — |
NCT03285321CT.gov Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT03215706CT.gov A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC | — | Completed | — | — | — |
NCT03262779CT.gov Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. | — | Completed | — | — | — |
NCT03158129CT.gov Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT03083691CT.gov BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer | — | Completed | — | — | — |
NCT03091491CT.gov Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03001882CT.gov An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT02864251CT.gov A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy | — | Completed | — | — | — |
NCT02998528CT.gov A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT02983045CT.gov A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors | — | Completed | — | — | — |
NCT02696993CT.gov Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT02922764CT.gov A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer | — | Completed | — | — | — |
NCT02658890CT.gov An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread | — | Completed | — | — | — |
NCT02659059CT.gov Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02477826CT.gov An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT02419495CT.gov Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT02381314CT.gov Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer | — | Completed | — | — | — |
NCT02350764CT.gov Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs | — | Completed | — | — | — |
NCT02279732CT.gov Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin | — | Completed | — | — | — |
NCT02259621CT.gov Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC | — | Active Not Recruiting | — | — | — |
NCT02221739CT.gov Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT02039674CT.gov A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) | — | Completed | — | — | — |
NCT01998126CT.gov Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT01840579CT.gov Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) | — | Completed | — | — | — |
NCT01820754CT.gov Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT01471197CT.gov Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT01454102CT.gov Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) | — | Completed | — | — | — |
NCT01165216CT.gov Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer | — | Completed | — | — | — |
NCT00527735CT.gov Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) | — | Completed | — | — | — |
NCT00039091CT.gov Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ipilimumab (this asset) | University of Chicago | P3 | BB · 67 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Ipilimumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P3 | BB · 71 |
| Melanoma | — | P4 | BB · 69 |
| Cutaneous Melanoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ipilimumab in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ipilimumab-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →